Mylan Faces Suit Over Orapred ANDA

Law360, New York (December 17, 2010, 3:58 PM EST) -- Shionogi Pharma Inc. and Cima Labs Inc. have filed a patent infringement suit over Mylan Inc.'s bid to introduce a generic version of anti-inflammatory Orapred ODT in various strengths.

Mylan confirmed Friday that the suit had been filed Dec. 9 in the U.S. District Court for the District of Delaware in response to the drugmaker's abbreviated new drug application for three different strengths of prednisolone sodium phosphate orally disintegrating tablets, a corticosteroid prescribed for the treatment of certain endocrine conditions, among other uses, and sold under...
To view the full article, register now.